Predictive value of peripheral lymphocyte subsets for the disease progression in patients with sepsis.

[1]  F. Kapadia,et al.  Immune Modulation and Cytomegalovirus Reactivation in Sepsis-induced Immunosuppression: A Pilot Study , 2021, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[2]  S. Sillau,et al.  1003. Cytokine Levels in Sepsis and TNFα Association with Mortality but not Sepsis Severity or Infection Source: a Systematic Review and Meta-analysis , 2021, Open Forum Infectious Diseases.

[3]  G. Parruti,et al.  Circulating lymphocyte subsets as promising biomarkers to identify septic patients at higher risk of unfavorable outcome , 2021, BMC Infectious Diseases.

[4]  V. Badovinac,et al.  Sepsis, Cytokine Storms, and Immunopathology: The Divide between Neonates and Adults , 2021, ImmunoHorizons.

[5]  R. Hotchkiss,et al.  IL-7 Immunotherapy in a Nonimmunocompromised Patient With Intractable Fungal Wound Sepsis , 2021, Open forum infectious diseases.

[6]  Kenneth G. C. Smith,et al.  Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease , 2021, Immunity.

[7]  Jun Yang,et al.  Predictive Value of Immune Cell Subsets for Mortality Risk in Patients With Sepsis , 2021, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[8]  A. Darzi,et al.  Sepsis , 2020, The Lancet.

[9]  Y. Long,et al.  [Diagnostic and prognostic value of peripheral lymphocyte subtyping for invasive candidiasis infection in critically ill patients with non-neutropenic sepsis]. , 2020, Zhonghua nei ke za zhi.

[10]  Jianbo Xu,et al.  Identification of key genes and novel immune infiltration-associated biomarkers of sepsis , 2020, Innate immunity.

[11]  W. Dolen,et al.  B Cell Disorders in Children: Part II , 2020, Current Allergy and Asthma Reports.

[12]  S. Stäger,et al.  Innate Immune Sensing by Cells of the Adaptive Immune System , 2020, Frontiers in Immunology.

[13]  Zhiyong Ma,et al.  Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia , 2020, The Journal of infectious diseases.

[14]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[15]  N. Hacohen,et al.  An immune-cell signature of bacterial sepsis , 2020, Nature Medicine.

[16]  Weifeng Yu,et al.  Impaired B-Cell Maturation Contributes to Reduced B Cell Numbers and Poor Prognosis in Sepsis. , 2019, Shock.

[17]  Muming Yu,et al.  Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis , 2019, Cell Death & Disease.

[18]  B. Söderquist,et al.  Trends in sepsis mortality over time in randomised sepsis trials: a systematic literature review and meta-analysis of mortality in the control arm, 2002–2016 , 2019, Critical Care.

[19]  C. Coopersmith,et al.  Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)* , 2019, Critical care medicine.

[20]  F. Tacke,et al.  Prognostic Relevance of Altered Lymphocyte Subpopulations in Critical Illness and Sepsis , 2019, Journal of clinical medicine.

[21]  M. Bauer,et al.  Sepsis induces long-lasting impairments in CD4+ T-cell responses despite rapid numerical recovery of T-lymphocyte populations , 2019, PloS one.

[22]  M. Hall.  Immune Modulation in Pediatric Sepsis , 2019, Journal of Pediatric Intensive Care.

[23]  J. Houtman,et al.  Polymicrobial sepsis influences NK-cell-mediated immunity by diminishing NK-cell-intrinsic receptor-mediated effector responses to viral ligands or infections , 2018, PLoS pathogens.

[24]  A. Seely,et al.  Clinical implications of the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , 2018, Canadian Medical Association Journal.

[25]  A. Choi,et al.  Determination of Early Immune Function in Sepsis and Its Influence on Organ Dysfunction. Is a More Pragmatic Outcome on the Horizon? , 2018, American journal of respiratory and critical care medicine.

[26]  D. Annane,et al.  Immune Effects of Corticosteroids in Sepsis , 2018, Front. Immunol..

[27]  M. Netea,et al.  Long‐term reprogramming of the innate immune system , 2018, Journal of leukocyte biology.

[28]  Yoshitsugu Yamada,et al.  Early-phase Innate Immune Suppression in Murine Severe Sepsis Is Restored with Systemic Interferon-&bgr; , 2018, Anesthesiology.

[29]  X. Guan,et al.  Thymosin alpha 1 treatment for patients with sepsis , 2018, Expert opinion on biological therapy.

[30]  Li Wei,et al.  High-doses Granulocyte Colony-stimulating Factor (G-CSF) Benefit Elderly Patients with Acute Myeloid Leukemia , 2018 .

[31]  R. Hotchkiss,et al.  Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. , 2018, JCI insight.

[32]  Dylan S. Small,et al.  Temporal Trends in Incidence, Sepsis-Related Mortality, and Hospital-Based Acute Care After Sepsis , 2018, Critical care medicine.

[33]  I. Martín-Loeches,et al.  Defects in innate and adaptive immunity in patients with sepsis and health care associated infection. , 2017, Annals of translational medicine.

[34]  M. Conaway,et al.  Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16). , 2017, The Journal of allergy and clinical immunology.

[35]  B. Wan,et al.  Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta‐analysis of Chinese and Indian patients☆,☆☆ , 2017, Journal of critical care.

[36]  F. Swirski,et al.  Cytokine storm and sepsis disease pathogenesis , 2017, Seminars in Immunopathology.

[37]  M. Singer,et al.  Activation-Associated Accelerated Apoptosis of Memory B Cells in Critically Ill Patients With Sepsis , 2017, Critical care medicine.

[38]  M. Delano,et al.  The immune system's role in sepsis progression, resolution, and long‐term outcome , 2016, Immunological reviews.

[39]  Tiansheng Wang,et al.  The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials , 2016, BMC Infectious Diseases.

[40]  W. Junger,et al.  Purinergic Signaling and the Immune Response in Sepsis: A Review. , 2016, Clinical therapeutics.

[41]  M. Delano,et al.  Sepsis-induced immune dysfunction: can immune therapies reduce mortality? , 2016, The Journal of clinical investigation.

[42]  Sun-Mee Lee,et al.  DAMPs activating innate immune responses in sepsis , 2015, Ageing Research Reviews.

[43]  E. Tønnesen,et al.  Expression of NK Cell and Monocyte Receptors in Critically Ill Patients – Potential Biomarkers of Sepsis , 2015, Scandinavian journal of immunology.

[44]  Y. Luan,et al.  Insights into the apoptotic death of immune cells in sepsis. , 2015, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[45]  M. Álvarez-Mon,et al.  Role of Circulating Lymphocytes in Patients with Sepsis , 2014, BioMed research international.

[46]  R. Hotchkiss,et al.  The new normal: immunomodulatory agents against sepsis immune suppression. , 2014, Trends in molecular medicine.

[47]  R. Hotchkiss,et al.  Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy , 2013, Nature Reviews Immunology.

[48]  T. van der Poll,et al.  Host innate immune responses to sepsis , 2013, Virulence.

[49]  V. Badovinac,et al.  Sustained and Incomplete Recovery of Naive CD8+ T Cell Precursors after Sepsis Contributes to Impaired CD8+ T Cell Responses to Infection , 2013, The Journal of Immunology.

[50]  R. Hotchkiss,et al.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. , 2013, The Lancet. Infectious diseases.

[51]  F. Venet,et al.  A rapidly progressing lymphocyte exhaustion after severe sepsis , 2012, Critical Care.

[52]  V. Giapros,et al.  Pre-inflammatory Mediators and Lymphocyte Subpopulations in Preterm Neonates with Sepsis , 2012, Inflammation.

[53]  A. Mejias,et al.  Cord blood interleukin‐6 as a predictor of early‐onset neonatal sepsis , 2012, Acta paediatrica.

[54]  C. Piantadosi,et al.  A Toll-Like Receptor 2 Pathway Regulates the Ppargc1a/b Metabolic Co-Activators in Mice with Staphylococcal aureus Sepsis , 2011, PloS one.

[55]  R. Hotchkiss,et al.  IL-7 Promotes T Cell Viability, Trafficking, and Functionality and Improves Survival in Sepsis , 2010, The Journal of Immunology.

[56]  S. Normark,et al.  Role of the innate immune system in host defence against bacterial infections: focus on the Toll‐like receptors , 2007, Journal of internal medicine.

[57]  N. Weng.  Aging of the immune system: how much can the adaptive immune system adapt? , 2006, Immunity.

[58]  Masayuki Yamamoto,et al.  Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. , 2006, The Journal of clinical investigation.

[59]  C. Hack,et al.  Activated cytotoxic T cells and NK cells in severe sepsis and septic shock and their role in multiple organ dysfunction. , 2005, Clinical immunology.

[60]  Jie Zhu,et al.  Prognostic value of circulating lymphocyte B and plasma immunoglobulin M on septic shock and sepsis: a systematic review and meta-analysis. , 2019, American journal of translational research.

[61]  F. Venet,et al.  IL-7 and Its Beneficial Role in Sepsis-Induced T Lymphocyte Dysfunction. , 2018, Critical reviews in immunology.

[62]  S. Kunkel,et al.  Regulation of Cellular Immune Responses in Sepsis by Histone Modifications. , 2017, Advances in protein chemistry and structural biology.